XBIT XBiotech Inc.
USHealthcareAs of 2026-07-10 16:00
Why XBIT matters now
XBiotech Inc. (XBIT) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.29 with +0.00% on the session and $69.8M in market capitalization; recent performance reads 1-month -2.53% and YTD -3.35%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.5M, and EPS of $-0.18. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -60.2%.
The latest indexable market news headline is "XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.52
P/S
0.00
EV/EBITDA
1.17
DCF Value
$4.08
FCF Yield
-60.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.1%
ROA
-28.7%
ROIC
-35.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.5M | $-0.18 |
| Q4 2025 | $0.00 | $-26.9M | $-0.88 |
| FY 2025 | $0.00 | $-45.5M | $-1.49 |
| Q3 2025 | $0.00 | $-6.0M | $-0.20 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.84
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.